Compare WSFS & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WSFS | INDV |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 1995 | 2014 |
| Metric | WSFS | INDV |
|---|---|---|
| Price | $69.28 | $33.43 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $70.80 | N/A |
| AVG Volume (30 Days) | 323.5K | ★ 1.6M |
| Earning Date | 04-23-2026 | 06-08-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | 15.42 | ★ 8100.00 |
| EPS | ★ 5.09 | 1.64 |
| Revenue | $963,949,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.40 | N/A |
| P/E Ratio | ★ $13.66 | $19.66 |
| Revenue Growth | ★ 50.18 | 4.29 |
| 52 Week Low | $48.64 | $10.21 |
| 52 Week High | $72.15 | $38.00 |
| Indicator | WSFS | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 60.44 | 58.87 |
| Support Level | $65.60 | $33.15 |
| Resistance Level | $70.88 | $35.75 |
| Average True Range (ATR) | 1.41 | 1.22 |
| MACD | 0.09 | 0.29 |
| Stochastic Oscillator | 60.01 | 93.09 |
WSFS Financial Corp is a savings and loan holding company. The company operates in three segments: WSFS Bank provides loans and leases and other financial products to commercial and consumer customers. Cash Connect segment provides ATM vault cash, smart safe, and other cash logistics services; and Wealth Management provides a broad array of planning and advisor services, investment management, personal and institutional trust services, and credit and deposit products to individuals, corporate, and institutional clients. Majority revenue is generated from WSFS Bank segment.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).